Literature DB >> 8619013

Vesamicol, an acetylcholine uptake blocker in presynaptic vesicles, suppresses rapid eye movement (REM) sleep in the rat.

R J Salin-Pascual1, A Jimenez-Anguiano.   

Abstract

Vesamicol inhibits acetylcholine uptake in presynaptic vesicles and reduce its release. The present study was performed in order to test the effects of this drug in a cholinergic related function as rapid eye movement (REM) sleep. Wistar male rats were implanted for sleep recordings. In addition, a stainless steel cannula was implanted into the left lateral ventricle for intracerebroventricular (ICV) injections. In experiment 1, a dose-response curve was performed. Saline or vesamicol (20, 40, 80 and 100 micrograms) were injected. Following the ICV injections, animals' sleep was recorded for 8 h. In experiment 2, after adaptation and baseline recordings, animals received 50 micrograms vesamicol ICV at 1000 hours. every 24 h for 2 consecutive days. After each injection an 8-h sleep recording session was performed. Two subsequent recovery recordings were allowed. Results obtained in experiment 1 showed a dose-response reduction of REM sleep with significant values at 80 micrograms and 100 micrograms of vesamicol. The main findings in experiment 2 were a reduction in REM sleep time and an increase in REM sleep latency. On the recovery days, a dramatic rebound of REM sleep was observed. Vesamicol behaved as an anticholinergic drug. It produced a reduction in REM sleep time and a rebound of this sleep stage after its withdrawal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619013     DOI: 10.1007/bf02246498

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Effects of biperiden on sleep at baseline and after 72 h of REM sleep deprivation in the cat.

Authors:  R J Salin-Pascual; A Jimenez-Anguiano; D Granados-Fuentes; R Drucker-Colin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effect of specific M1, M2 muscarinic receptor agonists on REM sleep generation.

Authors:  J Velazquez-Moctezuma; J C Gillin; P J Shiromani
Journal:  Brain Res       Date:  1989-11-27       Impact factor: 3.252

3.  Rapid-eye movement sleep and muscarinic receptor binding in rats are augmented during withdrawal from chronic scopolamine treatment.

Authors:  E L Sutin; P J Shiromani; J R Kelsoe; F I Storch; J C Gillin
Journal:  Life Sci       Date:  1986-12-22       Impact factor: 5.037

4.  A neuroanatomical gradient in the pontine tegmentum for the cholinoceptive induction of desynchronized sleep signs.

Authors:  H A Baghdoyan; M L Rodrigo-Angulo; R W McCarley; J A Hobson
Journal:  Brain Res       Date:  1987-06-30       Impact factor: 3.252

5.  The relative effects of selective M1 muscarinic antagonists on rapid eye movement sleep.

Authors:  R K Zoltoski; J Velazquez-Moctezuma; P J Shiromani; J C Gillin
Journal:  Brain Res       Date:  1993-04-16       Impact factor: 3.252

6.  Purification of the vesamicol receptor.

Authors:  B A Bahr; S M Parsons
Journal:  Biochemistry       Date:  1992-06-30       Impact factor: 3.162

7.  The effect of the acetylcholine transport blocker vesamicol on central cholinergic pressor neurons.

Authors:  J J Buccafusco; J Wei; K L Kraft
Journal:  Synapse       Date:  1991-08       Impact factor: 2.562

  7 in total
  2 in total

1.  Imaging in vivo acetylcholine release in the peripheral nervous system with a fluorescent nanosensor.

Authors:  Junfei Xia; Hongrong Yang; Michelle Mu; Nicholas Micovic; Kira E Poskanzer; James R Monaghan; Heather A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

2.  Cholinergic axons regulate type I acini in salivary glands of Ixodes ricinus and Ixodes scapularis ticks.

Authors:  Lourdes Mateos-Hernandéz; Baptiste Defaye; Marie Vancová; Ondrej Hajdusek; Radek Sima; Yoonseong Park; Houssam Attoui; Ladislav Šimo
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.